D.A. Davidson & Co. Cellectis S.A. Transaction History
D.A. Davidson & Co.
- $12.2 Billion
- Q1 2025
Shares
2 transactions
Others Institutions Holding CLLS
# of Institutions
30Shares Held
15MCall Options Held
0Put Options Held
0-
Ubs Asset Management Americas Inc Chicago, IL4.72MShares$6.85 Million0.0% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR4.72MShares$6.84 Million0.2% of portfolio
-
B Group, Inc. Dallas, TX3.26MShares$4.72 Million3.46% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.09 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$328,9680.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $66M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...